Now accepting Telehealth appointments. Schedule a virtual visit.

Female Sexual Wellbeing in Pre-menopausal Women: A New Indication for DHEA

Female Sexual Wellbeing in Pre-menopausal Women

CONFLICT STATEMENT: Readers of this article should be aware that CHR and CHR investigators have applied for an U.S. patent, claiming here described effects of DHEA and of other androgens on female sexual dysfunction in premenopausal women. If awarded, the patent will be exclusively licensed to Fertility Nutraceuticals, LLC, the same company that also currently holds licenses of other DHEA/androgen-related patents CHR and CHR investigators earned over the years for treatment of female infertility. In case this patent is awarded, Drs. Kushnir, Barad and Gleicher as well as CHR, as co-inventors, will receive financial benefits from that company. Dr. Gleicher is also a shareholder in Fertility Nutraceuticals, LLC and serves on its Board.


After for the longest time, primarily being interested only in male sexual dysfunction, the medical community and lay media have been paying increasing attention to female sexual dysfunction in recent years as well. The medical literature, indeed, created a new diagnostic terminology for this purpose by describing female sexual dysfunction as Hypoactive Sexual Desire Disorder or HSDD.

Readers of these pages will recall that CHR investigator recently published a study in the medical endocrinology literature, in which they demonstrated that DHEA in premenopausal women to highly significant degrees improved almost all aspects of sexual health, from sexual desire to even pelvic pain though to a lesser degree [Kushnir et al., Endocrine 2019; 63(3):632-638]. The study was conducted using the Female Sexual Function Index (FSFI), a widely used questionnaire to assess female sexual dysfunction in a variety of forms.

The study was unique for a number of reasons:

Female Sexual Wellbeing in Pre-menopausal Women

DHEA significantly improved libido, desire, arousal, orgasm and other aspects of sexual health, particularly in women with low baseline satisfaction scores. The graph above depicts the improvements in women with the lowest satisfaction before the study.

That androgen supplementation alleviates sexual dysfunction in postmenopausal women has been known for some time and the Food and Drug Administration (FDA) recently even approved a DHEA product for treatment of selective symptoms in postmenopausal women. That DHEA, by converting in the body to testosterone, is also so effective in premenopausal women has not been known before. CHR and CHR’s investigators, therefore, filed for a U.S. patent, once the study’s very significant results became apparent. Moreover, Fertility Nutraceuticals, LLC, a company CHR has a long-standing development relationship with for a number of fertility-related nutraceuticals, just launched a new product, called VIVO, specifically geared at premenopausal women with HSDD symptoms.

VIVO is a DHEA product which, like Fertinatal® DHEA for infertility, is given to raise testosterone. Since our bodies make testosterone from DHEA, this is the most physiological way to supplement low testosterone levels. Dosing is identical to DHEA fertility usages, expected side effects are also identical (discussed in detail in this article or on this DHEA side effects page). In the U.S., DHEA is considered a dietary supplement and does not require a prescription. However, as noted elsewhere in this issue of the VOICE, since DHEA is a natural hormone in our bodies, CHR considers it as such and, therefore, believes that, like other DHEA products, VIVO should be used for supplementation only under physician supervision.

VIVO for female sexual health is available

VIVO for female sexual health is available from vivoforintimacy.com

CHR’s study of DHEA as potential treatment of HSDD used the dosage of 25mg three times daily because this is the dosage usually prescribed to infertile women. Following the CHR study, VIVO was dosed accordingly by the manufacturer. It is, however, entirely possible that dosage requirements may be somewhat variable between patients. Like other products from Fertility Nutraceuticals, LLC, CHR now has VIVO available for purchase in the office.

Norbert Gleicher, MD

Norbert Gleicher, MD, FACOG, FACS

Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned specialist in reproductive endocrinology, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.

Follow on LinkedIn    

Watch his videos on YouTube    

 


We have helped women bring over
17,800 babies into the world.

DISCOVER YOUR TREATMENT OPTIONS

 

You Might Also Enjoy...

The Voice June 2022

We are pleased to present here the June issue of the CHR VOICE, after which we traditionally start a two-month summer hiatus for this newsletter, returning to our regular monthly publication schedule with the start of the new 2022-2023...

The Voice May 2022

April was a hectic month at the CHR because the deadline period for abstract submission to the Annual Meeting of the ASRM is always hectic.

The Voice April 2022

March was an unusually busy month at the CHR and not only clinically. CHR’s investigators saw several important papers published, with one in NATURE Medicine, in detail presented in the March issue of the VOICE, receiving unusual media attention

The Voice March 2022

With Spring per schedule knocking on the door, the mood in the world feels anything but spring-like. The deadly and cruel Russian war machine is already for weeks invading the independent country of Ukraine.

The Voice February 2022

In the shortest and traditionally coldest month of the year, we welcome you to the February issue of our monthly newsletter. Hopefully, history will show that we reached a point in the Covid-19 pandemic with more hope than at any time slot before.